Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study

PURPOSE: Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolon...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Colleoni, Marco, Giobbie-Hurder, Anita, Regan, Meredith M., Thürlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert, Láng, István, Smith, Ian, Chirgwin, Jacquie, Pienkowski, Tadeusz, Wardley, Andrew, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2011
נושאים:
Original Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3083867/
https://ncbi.nlm.nih.gov/pubmed/21321298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.6455
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים